Claims for Patent: 10,947,244

Summary for Patent: 10,947,244

Title:	Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations
Abstract:	The present invention relates to solid state forms of a p-toluenesulfonic acid salt (PTSA) of the selective PI3K delta inhibitor (S)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one (TGR-1202). The present invention also relates to methods of preparing the same, pharmaceutical compositions containing them, and methods of treating a PI3K kinase mediated disease or disorder, such as cancer, by administering the same.
Inventor(s):	Swaroop K. VAKKALANKA
Assignee:	Rhizen Pharmaceuticals AG
Application Number:	US16/557,091
Patent Claims:	1. A method for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia, peripheral T-cell lymphoma, or Hodgkin's lymphoma comprising the step of administering to a subject in need thereof an effective amount of a p-toluenesulfonic acid salt of the compound wherein the salt has a d(0.9) of from about 5 to about 50 μm. 2. A method for treating non-Hodgkin's lymphoma in a subject in need thereof comprising the step of administering to the subject an effective amount of a p-toluenesulfonic acid salt of the compound wherein the salt has a d(0.9) of from about 5 to about 50 μm. 3. A method for treating chronic lymphocytic leukemia in a subject in need thereof comprising the step of administering to the subject an effective amount of a p-toluenesulfonic acid salt of the compound wherein the salt has a d(0.9) of from about 5 to about 50 μm. 4. A method for treating follicular lymphoma in a subject in need thereof comprising the step of administering to the subject an effective amount of a p-toluenesulfonic acid salt of the compound wherein the salt has a d(0.9) of from about 5 to about 50 μm. 5. The method of claim 1, wherein the salt has a d(0.9) of from about 5 to about 25 μm. 6. The method of claim 2, wherein the salt has a d(0.9) of from about 5 to about 25 μm. 7. The method of claim 3, wherein the salt has a d(0.9) of from about 5 to about 25 μm. 8. The method of claim 4, wherein the salt has a d(0.9) of from about 5 to about 25 μm. 9. The method of claim 1, wherein the salt has a d(0.9) of from about 5 to about 15 μm. 10. The method of claim 2, wherein the salt has a d(0.9) of from about 5 to about 15 μm. 11. The method of claim 3, wherein the salt has a d(0.9) of from about 5 to about 15 μm. 12. The method of claim 4, wherein the salt has a d(0.9) of from about 5 to about 15 μm. 13. The method of claim 1, wherein the salt has a d(0.5) of from about 1 to about 10 μm. 14. The method of claim 2, wherein the salt has a d(0.5) of from about 1 to about 10 μm. 15. The method of claim 3, wherein the salt has a d(0.5) of from about 1 to about 10 μm. 16. The method of claim 4, wherein the salt has a d(0.5) of from about 1 to about 10 μm. 17. The method of claim 1, wherein the salt has a d(0.5) of from about 2 to about 5 μm. 18. The method of claim 2, wherein the salt has a d(0.5) of from about 2 to about 5 μm. 19. The method of claim 3, wherein the salt has a d(0.5) of from about 2 to about 5 μm. 20. The method of claim 4, wherein the salt has a d(0.5) of from about 2 to about 5 μm. 21. The method of claim 1, wherein the salt exhibits a XRPD pattern having one or more peaks selected from 5.0, 10.1, 22.1, and 24.5±0.2° 2Θ. 22. The method of claim 2, wherein the salt exhibits a XRPD pattern having one or more peaks selected from 5.0, 10.1, 22.1, and 24.5±0.2° 2Θ. 23. The method of claim 3, wherein the salt exhibits a XRPD pattern having one or more peaks selected from 5.0, 10.1, 22.1, and 24.5±0.2° 2Θ. 24. The method of claim 4, wherein the salt exhibits a XRPD pattern having one or more peaks selected from 5.0, 10.1, 22.1, and 24.5±0.2° 2Θ. 25. The method of claim 1, wherein the ratio of p-toluenesulfonic acid to the compound is about 1:1. 26. The method of claim 2, wherein the ratio of p-toluenesulfonic acid to the compound is about 1:1. 27. The method of claim 3, wherein the ratio of p-toluenesulfonic acid to the compound is about 1:1. 28. The method of claim 4, wherein the ratio of p-toluenesulfonic acid to the compound is about 1:1. 29. A method for the treatment of indolent non-Hodgkin's lymphoma comprising the step of administering to a subject in need thereof an effective amount of a p-toluenesulfonic acid salt of the compound wherein the salt has a d(0.9) of from about 5 to about 50 μm. 30. The method of claim 29, wherein the salt has a d(0.9) of from about 5 to about 25 μm. 31. The method of claim 29, wherein the salt has a d(0.9) of from about 5 to about 15 μm. 32. The method of claim 29, wherein the salt has a d(0.5) of from about 1 to about 10 μm. 33. The method of claim 29, wherein the salt has a d(0.5) of from about 2 to about 5 μm. 34. The method of claim 29, wherein the salt exhibits a XRPD pattern having one or more peaks selected from 5.0, 10.1, 22.1, and 24.5±0.2° 2Θ. 35. The method of claim 29, wherein the ratio of p-toluenesulfonic acid to the compound is about 1:1. 36. The method of claim 1, wherein the salt is administered orally. 37. The method of claim 2, wherein the salt is administered orally. 38. The method of claim 3, wherein the salt is administered orally. 39. The method of claim 4, wherein the salt is administered orally. 40. The method of claim 29, wherein the salt is administered orally.